Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

PF-06700841

Generic Name: PF-06700841

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₁F_₂N_₇O

CAS Number: 1883299-62-4

Unique Ingredient Identifier: 3X8387Q25N

Overview

PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers).

Background

PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

Phase 2

Completed

Posted: 2021/10/13

Sponsor:

Emma Guttman

ID:NCT05076006

Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations

Phase 1

Completed

Posted: 2020/10/08

Sponsor:Pfizer

ID:NCT04580797

Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids

Phase 1

Completed

Posted: 2020/02/12

Sponsor:Pfizer

ID:NCT04267250

Renal Impairment Study of PF-06700841

Phase 1

Completed

Posted: 2020/02/07

Sponsor:Pfizer

ID:NCT04260464

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Phase 2

Completed

Posted: 2019/09/17

Sponsor:Pfizer

ID:NCT04092452

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy